TACSTD2 and triple-negative breast carcinoma: In addition, in a clinical trial examining targeted ADC therapy for Trop2 in triple-negative breast cancer, patients who showed higher Trop2 expression displayed a tendency for elevated objective response rates and longer progression-free survival in comparison to those with lower expression level (Bardia et al, 2021b).